Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Opko

- PMLiVE

Novo launches haemophilia tracking app

Will compete with similar apps from Pfizer, Baxter

- PMLiVE

MP: Daiichi Sankyo’s expansion is endorsement of UK life sciences

Pharma company enlarges its UK early-stage development base

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Pfizer launches personalised lung cancer drug Xalkori in UK

Becomes first treatment on the market for ALK-positive NSCLC

- PMLiVE

Pfizer uses augmented reflection technology for mental health campaign

Teams up with Anxiety UK to raise awareness of GAD

- PMLiVE

Pfizer concludes NextWave acquisition

Sets company up to compete in the ADHD sector

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Was VP global commercial disease area lead for pain at Pfizer

- PMLiVE

Novartis calls for improvements to UK clinical trial system

Says cost of running studies in the country undermines its attractiveness

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

Cystic fibrosis group pledges $58m to Pfizer discovery programme

Pharma company forms public-private partnership with Cystic Fibrosis Foundation

- PMLiVE

Novo Nordisk’s new insulin moves closer to US approval

Follows recommendation in Europe

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links